AKTS
Akoustis Technologies Inc

3,035
Mkt Cap
$1.05B
Volume
152,177.00
52W High
$29.16
52W Low
$0.0372
Price
$19.69
AKTS Fundamentals
Prev Close
$19.77
Open
$19.51
50D MA
$19.38
Beta
0.00
Avg. Volume
231,207.17
EPS (Annual)
-$0.8374
P/B
-11.83
Loading...
Loading...
News
all
press releases
Aktis Oncology (NASDAQ:AKTS) Stock Price Up 7.2% - Here's What Happened
Aktis Oncology (NASDAQ:AKTS) Trading 7.2% Higher - Should You Buy...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs
Aktis Oncology (NASDAQ:AKTS) executives outlined the company's strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel...
MarketBeat·8d ago
News Placeholder
HC Wainwright Begins Coverage on Aktis Oncology (NASDAQ:AKTS)
HC Wainwright started coverage on shares of Aktis Oncology in a research report on Monday. They issued a "buy" rating and a $30.00 price target for the company...
MarketBeat·8d ago
News Placeholder
Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference
Aktis Oncology (NASDAQ:AKTS) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its strategy to broaden the reach of targeted radiopharmaceutical therapy beyond today's...
MarketBeat·14d ago
News Placeholder
Aktis Oncology's Quiet Period Set To End on February 18th (NASDAQ:AKTS)
Aktis Oncology's (NASDAQ:AKTS - Get Free Report) quiet period is set to expire on Wednesday, February 18th. Aktis Oncology had issued 17,650,000 shares in its public offering on January 9th. The...
MarketBeat·1mo ago
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Coverage Initiated at TD Cowen
TD Cowen started coverage on shares of Aktis Oncology in a report on Tuesday. They issued a "buy" rating for the company...
MarketBeat·1mo ago
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Now Covered by Bank of America
Bank of America began coverage on Aktis Oncology in a research report on Tuesday. They issued a "buy" rating and a $34.00 price target on the stock...
MarketBeat·1mo ago
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Now Covered by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. began coverage on Aktis Oncology in a research note on Tuesday. They issued an "overweight" rating and a $30.00 target price on the stock...
MarketBeat·1mo ago
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Leerink Partners
Leerink Partners assumed coverage on shares of Aktis Oncology in a report on Tuesday. They set an "outperform" rating and a $31.00 price objective on the stock...
MarketBeat·1mo ago
News Placeholder
Aktis Oncology (NASDAQ:AKTS) Shares Down 7.1% - Here's What Happened
Aktis Oncology (NASDAQ:AKTS) Stock Price Down 7.1% - Here's Why...
MarketBeat·2mo ago
<
1
2
...
>

Latest AKTS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.